Pfizer Inc.

NYSE:PFE  
52.47
+1.82 (+3.59%)
5:09:00 PM EDT: $52.42 -0.05 (-0.10%)
Production Guidance

BRIEF-SOBI To Cease ReFacto Production In Q1 2024

Published: 03/23/2022 14:25 GMT
Pfizer Inc. (PFE) - March 23 (reuters) - Swedish Orphan Biovitrum Ab (publ) :.
To Cease Refacto Production in Q1 2024.
Sobi Will Begin the Process of Reducing the Manufacturing Unit in Stockholm During the Second Half of 2022, With the Delivery of the Last Volumes to Pfizer in Early 2024.
Today's Announcement is Not Expected to Affect the Financial Outlook for 2022 and Revenues Are Expected to Be Offset by Productivity Improvements After 2023.
In Upcoming 24 Months Estimated 80 Employees Will Be Affected by Closure.
Its Contract With Pfizer for the Manufacture of Drug Substance for Refacto Af®/xyntha® (refacto) Has Been Amended Due to Clarity of Final Order Volumes and Will Now Expire in the First Quarter of 2024, Earlier Than the Previous Expiry Date at the End of 2025.